- Home
- GNFT vs NKTR Comparison
GNFT vs NKTR Comparison
Compare GNFT & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- NKTR
- Stock Information
- Founded
- GNFT 1999
- NKTR 1990
- Country
- GNFT France
- NKTR United States
- Employees
- GNFT N/A
- NKTR N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- NKTR Health Care
- Exchange
- GNFT Nasdaq
- NKTR Nasdaq
- Market Cap
- GNFT N/A
- NKTR 160.4M
- IPO Year
- GNFT 2019
- NKTR 1994
- Fundamental
- Price
- GNFT $3.32
- NKTR $0.68
- Analyst Decision
- GNFT Strong Buy
- NKTR Strong Buy
- Analyst Count
- GNFT 1
- NKTR 5
- Target Price
- GNFT $13.00
- NKTR $5.50
- AVG Volume (30 Days)
- GNFT 9.0K
- NKTR 1.5M
- Earning Date
- GNFT 04-24-2025
- NKTR 03-12-2025
- Dividend Yield
- GNFT N/A
- NKTR N/A
- EPS Growth
- GNFT N/A
- NKTR N/A
- EPS
- GNFT 0.47
- NKTR N/A
- Revenue
- GNFT $86,225,222.00
- NKTR $98,427,000.00
- Revenue This Year
- GNFT $145.20
- NKTR N/A
- Revenue Next Year
- GNFT N/A
- NKTR N/A
- P/E Ratio
- GNFT $7.66
- NKTR N/A
- Revenue Growth
- GNFT 175.45
- NKTR 9.21
- 52 Week Low
- GNFT $3.11
- NKTR $0.65
- 52 Week High
- GNFT $6.42
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- GNFT 45.10
- NKTR 31.49
- Support Level
- GNFT $3.35
- NKTR $0.84
- Resistance Level
- GNFT $3.68
- NKTR $0.92
- Average True Range (ATR)
- GNFT 0.08
- NKTR 0.07
- MACD
- GNFT 0.01
- NKTR -0.02
- Stochastic Oscillator
- GNFT 37.50
- NKTR 3.95
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.